| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The NHS ester functional group on CY5-SE triethylamine salt targets primary amines (-NH₂) on proteins, peptides, and oligonucleotides. The compound does not target a specific protein or enzyme but rather serves as a covalent labeling reagent that attaches the Cy5 fluorophore to amine-containing biomolecules. Cy5 is a hydrophilic cyanine dye with far-red fluorescence (Ex/Em=646/662 nm), providing low background and good tissue penetration. The triethylamine salt form enhances solubility.
|
|---|---|
| ln Vitro |
Advice (This is our suggested protocol, which should be adjusted to suit your particular circumstances as it simply offers guidance). SELP analogues conjugated to Cy5-SE. 1. Combine 10 μL of 1.2 mg/mL Cy5 monoNHS-ester in DMSO with 1 mL of 100 μg/mL SELP solution in 100 mM sodium bicarbonate buffer (pH 8.3), then let it sit on ice for two hours. ..2. To quench the reaction, add 50 μL of 1 M Tris-HCl (pH 8.0) to the reaction solution. 3. Centrifugation at 1050g[1] for three minutes is the method used to elute the Cy5-conjugated SELP after loading the reaction mixture onto a 1.5 mL Sephadex G-25 column.
The in vitro activity of CY5-SE triethylamine salt is its function as an amine-reactive fluorescent probe. The NHS ester reacts with primary amines to form stable amide bonds. The Cy5 fluorophore provides far-red fluorescence with excitation/emission maxima of 646/662 nm, making labeled conjugates detectable by fluorescence microscopy, flow cytometry, or other fluorescence-based methods. The compound is ideal for labeling soluble proteins, peptides, and oligonucleotides. |
| ln Vivo |
In vivo, CY5-SE triethylamine salt is not used as a therapeutic agent. However, Cy5-SE-conjugated ligands have been used in the characterization of hematopoietic tumor microenvironments, indicating its utility in research applications involving in vivo imaging.
|
| Enzyme Assay |
In vitro labeling assays for CY5-SE triethylamine salt involve incubating the NHS ester with amine-containing biomolecules in appropriate buffer conditions (typically pH 7-9). The reaction proceeds through nucleophilic attack of the primary amine on the NHS ester carbonyl, forming a stable amide bond. Labeling efficiency can be assessed by measuring the fluorescence intensity of the conjugated product using fluorescence spectroscopy or by determining the dye-to-protein ratio.
|
| Cell Assay |
For in vitro cellular experiments, CY5-SE triethylamine salt is first conjugated to antibodies, proteins, or other targeting ligands via the NHS ester-amine reaction. The labeled conjugates are then purified and added to cell culture medium for incubation with target cells. After washing, cells are analyzed by fluorescence microscopy or flow cytometry. The far-red fluorescence provides low background and excellent signal-to-noise ratio.
|
| Animal Protocol |
For in vivo animal experiments, CY5-SE triethylamine salt-conjugated ligands can be used for imaging applications. The far-red fluorescence (Ex/Em=646/662 nm) provides good tissue penetration and low autofluorescence background, making it suitable for in vivo imaging studies. Conjugates can be administered to animal models for tracking biodistribution and target engagement.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of CY5-SE triethylamine salt have not been extensively characterized. The compound has a molecular weight of 855.07-855.089 g/mol and should be stored at 2-8°C.
|
| Toxicity/Toxicokinetics |
CY5-SE triethylamine salt is intended for research use only and not for human therapeutic or diagnostic applications. Standard laboratory safety precautions should be observed when handling this chemical reagent.
|
| References | |
| Additional Infomation |
CY5-SE triethylamine salt (CAS#: 1497420-70-8) is a hydrophilic amine-reactive fluorescent probe for labeling amino-groups in peptides, proteins, and oligonucleotides. It displays excitation/emission maxima of 646/662 nm and has been used in the characterization of hematopoietic tumor microenvironments. The compound has no clinical or therapeutic applications.
|
| Molecular Formula |
C43H58N4O10S2
|
|---|---|
| Molecular Weight |
855.07
|
| Exact Mass |
854.359
|
| CAS # |
1497420-70-8
|
| Related CAS # |
CY5-SE;146368-14-1
|
| PubChem CID |
154728096
|
| Appearance |
Purple to purplish red solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
59
|
| Complexity |
1750
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCN\1C2=C(C=C(C=C2)S(=O)(=O)[O-])C(/C1=C\C=C\C=C\C3=[N+](C4=C(C3(C)C)C=C(C=C4)S(=O)(=O)O)CCCCCC(=O)ON5C(=O)CCC5=O)(C)C.CCN(CC)CC
|
| InChi Key |
IFUMHFCOWWJPSC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C37H43N3O10S2.C6H15N/c1-6-38-29-18-16-25(51(44,45)46)23-27(29)36(2,3)31(38)13-9-7-10-14-32-37(4,5)28-24-26(52(47,48)49)17-19-30(28)39(32)22-12-8-11-15-35(43)50-40-33(41)20-21-34(40)42;1-4-7(5-2)6-3/h7,9-10,13-14,16-19,23-24H,6,8,11-12,15,20-22H2,1-5H3,(H-,44,45,46,47,48,49);4-6H2,1-3H3
|
| Chemical Name |
N,N-diethylethanamine;(2E)-2-[(2E,4E)-5-[1-[6-(2,5-dioxopyrrolidin-1-yl)oxy-6-oxohexyl]-3,3-dimethyl-5-sulfoindol-1-ium-2-yl]penta-2,4-dienylidene]-1-ethyl-3,3-dimethylindole-5-sulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (146.19 mM)
H2O: ≥ 5.88 mg/mL (6.88 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: 25 mg/mL (29.24 mM) in Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1695 mL | 5.8475 mL | 11.6949 mL | |
| 5 mM | 0.2339 mL | 1.1695 mL | 2.3390 mL | |
| 10 mM | 0.1169 mL | 0.5847 mL | 1.1695 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
